SHATTUCK LABS INC (STTK)
Health Care · Biotechnology · NASDAQ
A clinical-stage biotech developing potentially first-in-class DR3-blocking antibodies to improve treatment outcomes for inflammatory and immune-mediated diseases like Crohn's.
What SHATTUCK LABS INC does
Shattuck Labs is a clinical-stage biotechnology company focused on the development of DR3-blocking monoclonal and bispecific antibodies to treat inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is designed to provide a more complete and durable blockade of the TL1A/DR3 signaling pathway compared to current TL1A-targeted therapies. The company is also developing SL-846, a bispecific antibody that co-targets DR3 and the IL-23 receptor.
Recent developments
Reported positive Phase 1 clinical data for SL-325 in June 2026, demonstrating a favorable safety and immunogenicity profile. The company expects to initiate the RECEPTIVE-CD1 Phase 2b clinical trial for SL-325 in Crohn's disease in Q3 2026. Shattuck also announced its new lead bispecific candidate, SL-846, with clinical trials expected in 2027.
From SHATTUCK LABS INC's filing of 2026-08-11.
Themes: Inflammatory and immune-mediated diseases, Crohn's disease treatment, Ulcerative colitis treatment, Autoimmune research, Next-generation antibody therapeutics
Fundamentals
- Price$5.58 as of 2026-10-21 close
- Market cap$560M as of 2026-08-07 (share count; price 2026-10-21)
- 1-year return+190.6% 2025-10-21 close $1.92 → 2026-10-21 close $5.58
- P/En/a negative earnings
- Net margin-4880.9% FY2025, SEC XBRL
- ROE-59.2% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-82.5% FY2025, SEC XBRL
- Revenue CAGR (3y)+15.3% SEC XBRL
- Beta1.31 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How STTK compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $0 | -$16M | -$15M | -$0.12 | -$10M† | — |
| Q1 FY2026 2026-03-31 | $0 | -$16M | -$15M | -$0.13 | -$13M | — |
| Q4 FY2025 2025-12-31 | — | -$13M† | -$13M† | -$0.08† | -$8M† | $0† |
| Q3 FY2025 2025-09-30 | $1M | -$11M | -$10M | -$0.14 | -$9M† | $71000† |
| Q2 FY2025 2025-06-30 | $0 | -$13M | -$12M | -$0.24 | -$10M† | — |
| Q1 FY2025 2025-03-31 | $0 | -$14M | -$14M | -$0.27 | -$12M | — |
| Q4 FY2024 2024-12-31 | — | -$20M† | -$19M† | -$0.37† | -$17M† | $0† |
| Q3 FY2024 2024-09-30 | $3M | -$18M | -$17M | -$0.33 | -$16M† | $42000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$63M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How SHATTUCK LABS INC looks technically
SHATTUCK LABS INC (STTK) is trading 6.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 269 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 33.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.3% below its 200-day average, the long-term trend line — a long-term downtrend | -6.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.53 | $6.53 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.95 | $5.95 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 5.193. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 269 trading days ago — a "golden cross", a bullish long-term signal | 269 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($5.19 to $7.09) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 20.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.33 | $8.33 |
|---|---|---|
| From the 52-week high | it is 33.0% below its 52-week high (its highest price of the past year) | -33.0% |
| Above the 52-week low | it is 228.2% above its 52-week low (its lowest price of the past year) | +228.2% |
| Below the 52-week high | it is 33.0% below its highest point of the past year | 33.0% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $46.76 (set on 2021-02-22) | $46.76 |
| Given back of the 52-week move | over the past year its closes ranged ($1.77 to $8.06), and it has given back roughly a third of its rise from last year’s low — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.97 to $4.17. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.4% |
| From the all-time high | it is 88.1% below its all-time high | -88.1% |
| Nearest price level | it is trading 3.0% below a resistance level at $5.75 — a price it turned at three times since 2026-03-23, most recently on 2026-09-16. Since 2024-10-21 it has 6 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.0% |
| All-time low | its lowest closing price on record is $0.692 (set on 2025-04-07) | $0.692 |
| Above the all-time low | it is 706.4% above its all-time low | +706.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4355 between its high and its low — about 7.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4355 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.02 and $6.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.02 – $6.00 – $6.99 |
| Typical daily range (% of price) | its price moves about 7.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.8% |
| Stretch from the 200-day average | it is trading 0.9 daily ranges below its 200-day average price (6.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.81× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 3.1% gap down opened on 2026-10-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.6 percentage points (the stock lost 8.7% while the market lost 0.1%) | -8.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 25.9 percentage points (the stock lost 22.6% while the market gained 3.3%) | -25.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 37.9 percentage points (the stock lost 28.1% while the market gained 9.8%) | -37.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 175.5 percentage points (the stock gained 190.6% while the market gained 15.2%) | +175.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.9% of the share price. | -18.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.09 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | -8.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $6.43 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -13.3% |
Price levels it has turned at before
STTK last closed at $5.58 on 2026-10-21. Since 2024-10-21 it has turned at 6 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.75 | Resistance | 3.0% above the last close | turned there three times · 2026-03-23 to 2026-09-16 |
| $7.64 | Resistance | 36.9% above the last close | turned there twice · 2026-04-09 to 2026-07-06 |
| $2.13 | Support | 61.7% below the last close | turned there twice · 2025-09-26 to 2025-10-20 |
| $1.71 | Support | 69.3% below the last close | turned there twice · 2025-10-15 to 2025-11-14 |
| $1.39 | Support | 75.1% below the last close | turned there three times · 2024-10-29 to 2025-03-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $5.19.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $5.78.
This reading has stood for 1 trading day, since 2026-10-21.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$15.40 range $10.00 – $19.00; median $15.50
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for STTK
- Consensus EPS estimate-$0.105 next reporting period, as of 2026-10-20
- Estimate change, 30 days+$0.00163 from -$0.1066, on 2026-09-15, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products and a history of operating losses, which may never reach commercial viability.","Heavy reliance on the success of the lead candidate SL-325, and future pipeline programs like SL-846.","Potential for clinical trial failures or regulatory delays which could lead to significant stock price volatility."]
What changed in the latest 10-Q
AI-assisted comparison of STTK's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Risk Factors
- Added:
- New Item 5 (Other Information) section disclosing Rule 10b5-1 trading plans adopted by Chief Medical Officer Arunthathy Nirmalini Pandite on February 2, 2026 for up to 83,514 shares, expiring June 30, 2027 or earlier
- New Item 5 disclosing Rule 10b5-1 trading plan adopted by Chief Technical Officer Abhinav Shukla on February 2, 2026 for stock options to purchase up to 168,659 shares, expiring January 29, 2027 or earlier
- New Item 5 statement confirming no other directors or Section 16 officers adopted or terminated trading arrangements during the three months ended March 31, 2026
- New Item 6 Exhibits section listing exhibits including First Amendment to Texas Lease Agreement (10.1) and Second Amendment to Texas Lease Agreement (10.2)
- New signature section dated May 07, 2026 with signatures from Dr. Taylor Schreiber (CEO) and Andrew R. Neill (CFO)
- Removed:
- Risk factor text regarding capital requirements and funding for SL-325 development
- Risk factor text regarding common stock warrants and their exercise implications
- Risk factor text regarding additional capital and management diversion
- Risk factor text regarding FDA disruptions from government shutdowns and leadership changes
- Risk factor text regarding federal government shutdown since October 1, 2025
- Risk factor text regarding laws and regulations affecting drug pricing and commercialization (text appears truncated at 'Und')
- Reworded:
- Changed from 'Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. Other than the risk factors below, there have been no material changes' to 'Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes' - updated fiscal year reference from 2024 to 2025 and removed 'Other than the risk factors below' qualifier
- Notes:
- Older filing text appears truncated or incomplete at the end (cuts off mid-word at 'Und'), limiting ability to assess all changes in risk factors section
- The newer filing contains significantly more content (Items 2-6 and signatures) while the older filing excerpt provided focuses primarily on Item 1A risk factors
- The filing structure and content differ substantially between the two documents, suggesting these may be different sections or complete portions of different 10-Q filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 180 days · read to 2026-10-171 buy ($250000) · 6 sells ($591850) — 1 buying, 2 selling insiders
Most recent open-market transaction: 2026-07-02. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about STTK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding STTK as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,158,761
- Reported value $42,741,800
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about STTK's institutional holders → See what each manager we track holds →
Short interest (FINRA)
STTK had 10,947,042 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
STTK had 10.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.01 days to cover at the same settlement.
- Reported short interest (shares) 10,947,042
- Short interest (% of shares outstanding) 10.9%
- Prior settlement (shares) 6,808,662
- Reported change 60.78%
- Days to cover (reported) 6.01
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (ROG.SW)
- Merck & Co. (MRK)
- AbbVie (ABBV)
- Eli Lilly (LLY)
- Johnson & Johnson (JNJ)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare STTK vs…
Frequently asked questions
What does SHATTUCK LABS INC (STTK) do?
Shattuck Labs is a clinical-stage biotechnology company focused on the development of DR3-blocking monoclonal and bispecific antibodies to treat inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is designed to provide a more complete and durable blockade of the TL1A/DR3 signaling pathway compared to current TL1A-targeted therapies. The company is also developing SL-846, a bispecific antibody that co-targets DR3 and the IL-23 receptor.
What sector is SHATTUCK LABS INC (STTK) in?
SHATTUCK LABS INC (STTK) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are SHATTUCK LABS INC's (STTK) competitors?
Notable peers of SHATTUCK LABS INC (STTK) include Roche, Merck & Co., AbbVie, Eli Lilly and Johnson & Johnson. This peer set is informational only — not financial advice.
Is SHATTUCK LABS INC (STTK) overbought or oversold right now?
SHATTUCK LABS INC (STTK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on STTK come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.